Market cap
$33.6m
End-of-day close multiplied by current shares on issue.
PHL · NZX
Promisia Healthcare is an NZX-listed healthcare / aged care company. Its latest covered result is HY27, with FY22 - HY27 of source-backed result history on Annolyse.
Latest result
HY27, released 11 November 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $21.8m | ↑ +68.7% |
| EBITDAF | $3.8m | ↑ +139.4% |
| NPAT | $1.3m | — |
| Operating cash flow | $2.3m | ↑ +12.7% |
| OCF / EBITDAF % | 61.0% | ↓ -68.6pp |
| Net debt | $41.6m | ↑ +38.5% |
| Net debt / EBITDAF | 10.87x | ↓ -42.2% |
| ROE % | 2.3% | — |
| DPS | 0.7c | — |
| Payout ratio vs NPAT % | 28.9% | — |
Source: latest published briefing (HY27, released 11 November 2026). Change compares against the prior equivalent period: HY24, released 28 November 2023.
Valuation
Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.
The latest close and share count context for the market price.
Market cap
$33.6m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not available for this company right now.
EPS
Not available
Not available for this company right now.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not available for this company right now.
P/B
0.59x
Market value compared with latest reported equity.
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.
Chat
Ask follow-up questions about Promisia Healthcare's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Financial history
The latest period is shown first.
| Metric | HY276 MONTHS11 November 2026 | FY2612 MONTHS28 May 2026 | FY2412 MONTHS29 May 2024 | HY246 MONTHS28 November 2023 | FY2312 MONTHS30 May 2023 | FY2212 MONTHS30 June 2022 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | $21.8m | $40.1m | $29.9m | $12.9m | $23.8m | $19m | Chart |
| Revenue growth % | 13.7% | 29.1% | 25.6% | 10.7% | 25.5% | 213.6% | Chart |
| EBITDAF | $3.8m | $6.6m | — | $1.6m | $3.6m | $4.5m | Chart |
| EBITDAF margin % | 17.6% | 16.5% | — | 12.4% | 15.0% | 23.5% | Chart |
| PBT | $2m | $13.9m | $3.6m | -$0.1m | $0.5m | $1.9m | Chart |
| PBT growth % | 741.7% | 107.5% | 620.0% | — | -73.7% | — | Chart |
| NPAT | $1.3m | $12.9m | $1.6m | — | $0.7m | $2m | Chart |
| NPAT growth % | — | 89.7% | 128.6% | — | -65.0% | n/m | Chart |
| Operating cash flow | $2.3m | $6.4m | $7.5m | $2.1m | $7.1m | $4.8m | Chart |
| OCF / EBITDAF % | 61.0% | 96.2% | — | 129.6% | 197.5% | 107.1% | Chart |
| FCF pre-lease | $1.5m | $5.8m | — | — | -$6.8m | $4.3m | Chart |
| DPS | 0.7c | 0.0c | — | — | — | — | Chart |
| Payout ratio vs NPAT % | 28.9% | n/m | — | — | — | — | Chart |
| Annual payout ratio vs EPS % | — | n/m | n/m | — | — | — | Chart |
| ROE % | 2.3% | 23.4% | 6.6% | — | 3.4% | 10.9% | Chart |
| Net debt | $41.6m | $38.5m | $29m | $30.1m | $28.8m | $14.7m | Chart |
| Net debt / EBITDAF | 10.87x | 5.82x | — | 18.79x | 8.04x | 3.3x | Chart |
| Debtor days | — | — | — | 32 | 22 | 20 | Chart |
| Total assets | $202.8m | $199.5m | $84.3m | $73.6m | $71.8m | $51.5m | Chart |
Reference: annolyse.ai/companies/phl
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional filing-backed metrics for this company. Each point links to the relevant published briefing.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Dividend per share declared for the period.
Dividend payout against statutory NPAT.
Receivables days where the working-capital inputs are source-backed.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
Previous analysisFY26Result releasedAnnolyse analysis published
From FY26 NPAT $12.9m hinges on H2 swing; EBITDAF $6.6m the cleaner read
No quantitative forward targets are disclosed. The release describes Cromwell as now embedded and Nelson Street as effectively full, and the HY26 release referenced early-stage acquisition negotiations. The result supports the operational repositioning narrative at the EBITDAF level, but with H2 carrying virtually all reported earnings and a basis change from the acquisition and disposal, the forward run-rate cannot be cleanly inferred from the headline. Investors should weight EBITDAF rather than NPAT when projecting forward, and watch HY27 for confirmation that the H2 EBITDAF pace (roughly $4.1m on the implied split) reflects an underlying base rather than seasonal occupancy strength.
Open questions
This briefing cannot assess the specific composition of the $7.3m gap between EBITDAF and PBT because the source material does not separately disclose revaluation, fair-value, or other non-operating items.
Primary issuer documents used for the HY27 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.
PHL HY27 Interim Report
HY27 / financial reportPHL HY27 NZX Results Announcement
HY27 / results announcementPHL HY27 Results Announcement
HY27 / results releasePHL HY26 Preliminary Financial Statements
HY26 / financial reportPHL HY26 Results Announcement
HY26 / results releasePHL HY26 NZX Results Announcement
HY26 / results announcementPHL 2026 Annual Report
FY26 / financial reportFY26 Earnings Guidance Upgrade
FY26 / commentaryPresentation - ASM 2025
HY26 / commentaryPresentation - ASM 2026
HY27 / commentaryPeer context
These companies share the same curated sub-sector label. Their reporting definitions can still differ, so compare the underlying measures before ranking them.
Archive
The full chronological archive contains every published result briefing.
HY27 · Released 11 November 2026
The NZ$25m acquisition price is relevant to debt headroom, while borrowings and gearing remain the direct evidence.
FY26 · Released 28 May 2026
Full-year Cromwell consolidation and a sharp H2 earnings swing lift reported NPAT while net debt/EBITDAF falls to 5.8x.
FY24 · Released 29 May 2024
Revenue growth of 25.6% flatters the comparison because FY23 included a major acquisition, while a negative effective tax rate of -54.6% inflates
HY24 · Released 28 November 2023
Promisia's aged-care operations grew the top line solidly, but earnings turned negative as cost growth absorbed the revenue gain, leaving a NPAT loss
FY23 · Released 30 May 2023
A 25.5% revenue uplift was more than consumed by higher operating costs, lifting net debt to EBITDA to 8.0x and compressing PBT to NZ$0.5m.
FY22 · Released 30 June 2022
Headline +213.6% growth reflects the December 2020 acquisition lapping into a full period, not underlying expansion of the existing footprint.
Get the next Promisia Healthcare result briefing and five-year history updates by email.